Search results: (10000)
News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy
William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.
News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients
A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.
News Valproate and Lithium in Maintenance Therapy of Bipolar Affective Disorder
Among the so-called mood stabilizers, drugs commonly used in the therapy of bipolar affective disorder, are valproate and lithium. Canadian authors recently conducted a post hoc analysis of a study aimed at comparing their effectiveness in the maintenance treatment of bipolar I disorder.
News Anticonvulsants Are Associated with the Least Impact on Sexual Function in Bipolar Disorder Treatment
It is known that in patients with bipolar disorder, in addition to the illness itself, sexual dysfunction is adversely affected by psychotropic medications. A study by Spanish authors recently published in the Journal of Sexual Medicine compared the treatment of different groups of mood stabilizers in patients with bipolar disorder in terms of adverse effects on sexual function.
News Bilastine as a reliable helper in the treatment of allergic rhinoconjunctivitis and urticaria even in younger children
Until recently, bilastine was indicated for the treatment of allergic rhinoconjunctivitis and urticaria only in patients over 12 years of age. However, current findings from valid studies demonstrate the safety and efficacy of its use even in younger individuals.
News Incidence of Allergic Diseases in Children Probably Unrelated to Air Pollution
A recently published extensive meta-analysis of 7 cohorts of children aged 4 and 8 from 5 European countries investigated the relationship between air pollution at the child's place of residence and the incidence of allergic eczema, rhinoconjunctivitis, or asthma.
News Study PLATON: romiplostim in patients with ITP in real clinical practice
Recently, the results of the PLATON study with romiplostim, which was conducted in Central and Eastern European countries including the Czech Republic, were published. It was an observational non-interventional cohort study from real practice, and romiplostim was used within its approved indication.
News Chronic Thromboembolic Pulmonary Hypertension – Overview of Pathophysiology, Diagnosis, and Treatment
Chronic thromboembolic pulmonary hypertension (CTEPH) is defined by the 2015 ESC/ERS guidelines as symptomatic pulmonary hypertension with persistent defects in lung perfusion despite adequate anticoagulation therapy. Significant values for determining a diagnosis of pulmonary hypertension are a mean pulmonary artery pressure > 25 mmHg. However, this condition remains significantly underdiagnosed, mainly due to its nonspecific symptoms.
News Thyroid Disorder Screening in Pregnancy to Be Tested by Pilot Program Starting September
The expectations surrounding the trial launch of the screening program were discussed by Professor Michal Kršek, Chairman of the Czech Endocrinological Society ČLS JEP, on the occasion of the 12th annual “Thyroid Week”.
News “Think about the thyroid gland during pregnancy,” reminds awareness campaign
Thyroid disorders can endanger the health of both the fetus and the mother. Sometimes, however, the problem only manifests during pregnancy, and the expectant mother or her doctor might not notice it amidst other ongoing changes. The issue was highlighted by an event called “Thyroid Week,” which took place in the Czech Republic during the last week of May 2020.
News Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization of therapy based on the presence of specific tumor cell mutations is therefore crucial for choosing the optimal therapy for these patients. One of the targeted treatment options for patients with NSCLC with an activating mutation in the epidermal growth factor receptor (EGFR) gene is osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI). We present a case study of a patient with NSCLC treated with osimertinib after disease progression due to a secondary EGFR T790M mutation resulting from afatinib therapy. The described case well illustrates the role of osimertinib in the treatment of NSCLC with secondary EGFR T790M mutation.
News Use of Targeted Therapy with Dupilumab in Patients with Allergic Diseases
Interleukins (IL) 4 and 13 play an important role in the pathogenesis of allergic diseases. Their blockade is therefore a suitable strategy for a number of these conditions. This is offered by the new monoclonal antibody dupilumab (Dupixent), which is approved for the treatment of atopic dermatitis, asthma with type 2 inflammation, and chronic rhinosinusitis with nasal polyposis. Studies are ongoing to evaluate its efficacy in other diseases where type 2 inflammation predominates.
News Asthma is not a risk factor for a severe course of COVID-19
According to the statement of the Czech Initiative for Asthma from April 2020, the disease COVID-19 caused by the new type of coronavirus does not pose significantly greater danger for people with asthma than for the general population. It is, however, necessary to adhere to the prescribed treatment and keep asthma under control. The Journal of Allergy and Clinical Immunology provides an explanation for this surprising phenomenon. It is the reduced expression of ACE2 receptors in people with asthma and allergies, as shown by a new study involving three cohorts of pediatric and adult patients. The SARS-CoV-2 virus uses ACE2 receptors to enter the host cell.
News Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven activating mutation of the epidermal growth factor receptor (EGFR) gene, who developed resistance to the first-generation EGFR tyrosine kinase inhibitor (TKI) gefitinib during treatment. After the secondary mutation EGFR T790M was confirmed, osimertinib, a third-generation EGFR TKI, was introduced, resulting in disease regression, which is ongoing. This case study illustrates the significance of the role of osimertinib in the treatment of patients with NSCLC with an activating EGFR mutation, whose disease progresses during treatment with first and second-generation EGFR TKIs due to the emergence of the secondary EGFR T790M mutation.
News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab
At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.